Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Virtu Financial LLC

Virtu Financial LLC lifted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,669 shares of the company’s stock after acquiring an additional 167 shares during the quarter. Virtu Financial LLC’s holdings in Medpace were worth $1,551,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Pallas Capital Advisors LLC raised its position in Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after acquiring an additional 2,101 shares during the period. Barclays PLC raised its position in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after acquiring an additional 8,275 shares during the period. Sanctuary Advisors LLC raised its position in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after acquiring an additional 844 shares during the period. Loomis Sayles & Co. L P raised its position in Medpace by 7.2% during the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock worth $68,696,000 after acquiring an additional 13,880 shares during the period. Finally, Cerity Partners LLC raised its position in Medpace by 18.7% during the third quarter. Cerity Partners LLC now owns 61,890 shares of the company’s stock worth $20,659,000 after acquiring an additional 9,741 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Up 1.4 %

Shares of MEDP opened at $324.23 on Friday. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The firm has a 50-day moving average price of $337.72 and a 200 day moving average price of $339.82. The firm has a market capitalization of $9.88 billion, a P/E ratio of 25.67, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.